Skip to content
DSML.KZ
Publications

Article · Epidemiology and Infection · January 1, 2023

Study of seroprevalence of SARS‐CoV‐2 in Kazakhstan

Mukhtar Kulimbet, Timur M. Saliev, Gulzhan Alimbekova, Dinara Ospanova, Kundyzay Tobzhanova, Dariga Tanabayeva

Timur SalievIldar Fakhradiyev
Read on dx.doi.orgPDFDOI 10.1017/s0950268823001085

Abstract

Abstract This study aimed to analyse the seroprevalence of SARS-CoV-2 in Kazakhstan. This is a cross-sectional study of adult population in Kazakhstan for the period from October 2021 to May 2022. For the study, 6 720 people aged 18 to 69 were recruited (from 17 regions). The demographic data were collected and analysed. Gender was evenly distributed (males 49.9%, females 50.1%). Women exhibited a higher seroprevalence than men (IgM 20.7% vs 17.9% and IgG 46.1% vs 41.5%). The highest prevalence of IgM was found in the age group of 30–39. However, the highest prevalence of IgG was detected in the age group of 60–69. The seroprevalence of IgG increased across all groups (from 39.7% in 18–29 age groups to 53.1% in 60–69 age groups). The odds for a positive test were significantly increased in older age groups 50–59 (p < 0.0001) and 60–69 (p < 0.0001). The odds of a positive test were 1.12 times higher in females compared to males (p = 0.0294). The odds for a positive test were significantly higher in eight regions (Astana, Akmola, Atyrau, Western Kazakhstan region, Kostanai, Turkestan, Eastern Kazakhstan region, and Shymkent) compared to Almaty city. The odds of a positive test were three times higher in Astana and the Western Kazakhstan region than in Almaty city. In urban areas, the odds of a positive test were 0.75 times lower than in rural areas (p < 0.0001). The study’s results showed an adequate level of seroprevalence (63%) that exceeds the essential minimum of herd immunity indicators in the country. There was significant geographic variability with a higher prevalence of IgG/IgM antibodies to SARS-CoV-2 in rural areas.

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studiesCOVID-19 Clinical Research StudiesSARS-CoV-2seroprevalenceCOVID-19 pandemic

More by Timur Saliev